Infant formula recalls
This article was originally published in The Tan Sheet
Executive Summary
FDA is allowing 60 days for public comment regarding the requirements of its recall infant formula strategy, the agency announces in a March 26 Federal Register notice. Specifically, FDA invites comment on "ways to enhance the quality, utility and clarity of the information to be collected" and "ways to minimize the burden of the collection of information on respondents." Currently, firms initiating a recall are required to submit written report to FDA within 14 days and status reports every 14 days until the recall is terminated, among other requirements. The agency says there has been an average of two infant formula recalls per year for the past three years...
You may also be interested in...
Formula recall strategy
FDA received no comments on its infant formula recall strategy, the agency says in a June 24 Federal Register notice. The proposed information collection was submitted to the Office of Management and Budget for review and clearance, though comments on the collection may be submitted to OMB through July 24. In a March 26 Federal Register notice, FDA invited comment on enhancing the quality, utility and clarity of collected information (1"The Tan Sheet" March 31, 2008, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.